Table I.
TPE-treated N = 109 N (%) |
Non-TPE Treated N = 204 N (%) |
p | |
---|---|---|---|
| |||
Age (years), mean, SD | 48, 19 | 51, 19 | 0.45 |
Range | 4 mos. – 76 yrs. | 2 mos. – 74 yrs. | |
| |||
Pediatric patients (Age < 18) | 11 (10) | 20 (10) | 0.94 |
| |||
Sex | < 0.0001 | ||
Males | 59 (54) | 158 (77) | |
Females | 50 (46) | 46 (23) | |
| |||
Race | 0.0009 | ||
White/Caucasian | 56 (51) | 142 (70) | |
Black/African American | 48 (44) | 48 (23) | |
Other | 5 (5) | 14 (7) | |
| |||
Transplant year | 0.06 | ||
2010 | 22 (20) | 36 (18) | |
2011 | 28 (26) | 32 (16) | |
2012 | 17 (16) | 47 (23) | |
2013 | 24 (22) | 37 (18) | |
2014 | 18 (16) | 52 (25) | |
| |||
Transplant indication | |||
Non-ischemic cardiomyopathy | 58 (53) | 90 (44) | |
Ischemic cardiomyopathy | 34 (31) | 86 (42) | 0.02 |
Congenital Heart Defect | 12 (11) | 9 (5) | |
Other | 5 (5) | 19 (9) | |
| |||
Post-transplant infection present | 42 (39) | 76 (37) | 0.82 |
TPE = Therapeutic plasma exchange; N = Number; SD = Standard deviation; mos. = months; yrs. = years; p-values calculated using two-sample t-test and chi-square test of independence as appropriate.